The dual-positive cases accounted for 4.7% (5/106) of ALK-positive lung adenocarcinoma samples using direct sequencing, which was similar to the ratio of 4.4% (4/91) reported by Won et al. 13 but lower than the ratio of 18.6% (12/70) reported by Yang et al. 17; both studies used the same detection method. This evidence concerns the gene ALK and lung adenocarcinoma.